Direct oral anticoagulants for stroke prevention in patients with atrial fibrillation: meta‐analysis by geographic region with a focus on European patients
- 17 June 2016
- journal article
- review article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 82 (3) , 633-644
Abstract
AimsTo analyse clinical outcomes with direct oral anticoagulants in patients with atrial fibrillation according to geographic region. MethodsWe systematically searched MEDLINE, CENTRAL, websites of regulatory agencies, clinical trials registers and conference proceedings for randomized controlled trials of direct oral anticoagulants (DOAC: dabigatran, rivaroxaban, apixaban or edoxaban) against warfarin for prophylaxis of stroke and systemic embolic events (SEE) in patients with atrial fibrillation (AF). Two investigators independently extracted data. Relative risks of stroke and SEE as well as major bleeding depending on geographic region were estimated using a random effect meta-analysis. ResultsFive trials in 72963 patients were analysed; 32089 (44%) patients were recruited in Europe (Western Europe: 13676; Eastern Europe: 18413). We found significant subgroup differences for stroke/SEE depending on the geographic region (interaction P=0.003; I-2 88.5%), with a neutral effect of the DOAC vs. warfarin in Europe [relative risk (RR) 0.97, 95% confidence interval (CI) 0.85-1.11, I-2 0%] and a significant reduction of stroke/SEE in other regions including North America, Latin America and Asia-Pacific/other (RR 0.72, 95% CI 0.63-0.83, I-2 33%). There was a similar reduction in risk of major bleeding in Europe (RR 0.82, 95% CI 0.73-0.92, I-2 0%) and in other regions (RR 0.86, 95% CI 0.72-1.02, I-2 78%). ConclusionThe DOAC did not provide additional benefit in reducing the risk of stroke/SEE compared with warfarin in European patients with AF, but were generally associated with a lower bleeding tendency than warfarin regardless of geographic region.Keywords
This publication has 35 references indexed in Scilit:
- Balancing the Benefits and Risks of 2 Doses of Dabigatran Compared With Warfarin in Atrial FibrillationJACC, 2013
- Impact of Global Geographic Region on Time in Therapeutic Range on Warfarin Anticoagulant Therapy: Data From the ROCKET AF Clinical TrialJournal of the American Heart Association, 2013
- Geographic Variations in the Quality of Oral Anticoagulation With Vitamin K Antagonists in the Era of New AnticoagulantsJournal of the American Heart Association, 2013
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Safety and Efficacy of the Oral Direct Factor Xa Inhibitor Apixaban in Japanese Patients With Non-Valvular Atrial FibrillationCirculation Journal, 2011
- Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillationThrombosis and Haemostasis, 2011
- Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillationThrombosis and Haemostasis, 2010
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986